Questcor acquisition a step toward diversification, says Lazard Capital Lazard Capital views Questcor's acquisition of BioVectra as a step toward diversification and notes that in the press release, the company said it is now "in a better position to meet the continuing growth in demand for Acthar." Lazard Capital says the indication of growth contrasts with the bearish thinking on the stock and reiterates a Buy rating on Questcor.
News For QCOR From The Last 14 Days
Check below for free stories on QCOR the last two weeks.